Concepedia

Author

Pancras C. Wong

Bristol-Myers Squibb (United States)ORCID

Also Known As

Joseph Luettgen, P C Wong, P Wong, P. C. WONG, P. C. Wong, P. Wong, P.C. WONG, P.C. Wong, Pancras C Wong, Pancras C. Wong

197

Publications

12.8K

Citations

53

H-Index

64

Concepts

All Affiliations

Bristol-Myers Squibb (United States)DuPont (United States)Wilmington UniversityBristol-Myers Squibb (Germany)Experimental Station
PC

About

Pancras C. Wong is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

36

75

4.8K

2

Natural Sciences

19

26

1.4K

3

Biochemistry

19

25

1.4K

4

Biomolecular Engineering

4

4

296

5

Anesthesia

1

1

49

Pancras C. Wong

×

113

Publications

8.2K

Citations

48

H-Index

YearCitations

Identification of angiotensin II receptor subtypes

Andrew T. Chiu, William F. Herblin, Dale E. McCall,

Biochemical and Biophysical Research Communications

1989

822

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

Nirmala Raghavan, Charles Frost, Zhigang Yu,

Drug Metabolism and Disposition

2008

598

Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Stephanie C. Koch,

Journal of Medicinal Chemistry

2007

391

Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.

Pancras C. Wong, William A. Price, Andrew T. Chiu,

Journal of Pharmacology and Experimental Therapeutics

1990

330

Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.

Andrew T. Chiu, Dale E. McCall, William A. Price,

Journal of Pharmacology and Experimental Therapeutics

1990

317

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

Pancras C. Wong, Earl J. Crain, Bailong Xin,

Journal of Thrombosis and Haemostasis

2008

299

Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2).

Pancras C. Wong, S D Hart, Alverna M. Zaspel,

Journal of Pharmacology and Experimental Therapeutics

1990

294

Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.

Pancras C. Wong, William A. Price, Andrew T. Chiu,

Journal of Pharmacology and Experimental Therapeutics

1990

270

Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.

Pancras C. Wong, William A. Price, Andrew T. Chiu,

Journal of Pharmacology and Experimental Therapeutics

1990

203

Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-<i>N</i>-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1<i>H</i>-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

Mimi L. Quan, Patrick Y. S. Lam, Qi Han,

Journal of Medicinal Chemistry

2004

188

Page 1